Extracellular proteolysis and the migrating vascular smooth muscle cell

Fibrinolysis

Volumn 10, Issue 2, 1996, Pages 59-74

  Van Leeuwen, R T J ^a  

^a TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; PLASMINOGEN ACTIVATOR;

ARTERY; CELL MIGRATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0029931024     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80081-6     Document Type: Review

References (202)

1. Chamley J H, Campbell G R, McDonnell J D, Groeschell-Stewart U. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tissue Res 1977; 177: 503-22.
2. Chamley-Campbell J H, Campbell G R, Ross R. Phenotype-dependent response of cultured aortic smooth muscle cells to serum mitogens. J Cell Biol 1981; 89: 379-83.
3. Schwartz S M, Campbell G R, Campbell J H. Replication of smooth muscle cells in vascular disease. Circulation Res 1986; 58(4): 427-44.
4. Luscher T F. Endothelium in the control of vascular tone and growth: role of local mediators and mechanical forces. Blood Press 1994; Suppl 1: 18-22.
5. Nakayama K, Tanaka Y. Stretch-induced contraction and Ca2+ mobilization in vascular smooth muscle. Biol Signals. 1993; 2(5): 241-52.
6. Hishikawa K, Nakaki T, Marumo T, Hayashi M, Suzuki H, Kato R, Saruta T. Pressure promotes DNA synthesis in rat cultured vascular smooth muscle cells. J Clin Invest. 1994; 93(5): 1975-80.
7. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 1992; 86: 3: 723-9.
8. Carey D J. Control of growth and differentiation of vascular cells by extracellular matrix proteins. Annu Rev Physiol 1991; 53: 161-77.
9. Clowes A W, and Clowes M M. Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circulation Res 1986; 58: 839-45.
10. Fager G, Camejo G, Bondjers G. Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I. Evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin.: In Vitro Cell Dev Biol 1992; 28A; 168-75.
11. Fager G, Camejo G, Olsson U, Ostergren-Lunden G, Bondjers G. Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. II. The platelet-derived growth factor A-chain contains a sequence that specifically binds heparin. In Vitro Cell Dev Biol 1992; 28A: 176-180.
12. Palmberg L, Claesson H E, and Thyberg J. Effects of leucotriens on phenotypic properties and growth of arterial smooth muscle cells in primary culture. J Cell Sci 1989; 93: 403-08.
13. Yamamoto M, Yamamoto K, Noumura T. Type I collagen promotes modulation of cultured rabbit arterial smooth muscle cells from a contractile to a synthetic phenotype. Exp Cell Res 1993; 204(1): 121-129.
14. Casscells W, Speir E, Sasse J et al. Isolation, characterization, and localization of heparin-binding growth factors in the heart. J Clin Invest 1990; 85: 433-41.
15. Clowes A W. Prevention and management of recurrent desease after arterial reconstruction: New prospects for pharmacological control. Thromb Haemost 1991; 66(1): 62-66.
16. Jawien A, Bowen-Pope D F, Lindner V, Schwarz S M, Clowes A W. Platelet derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992; 89: 507-11.
17. Edelman E R, Nugent M A, Smith L T, Karnovsky M J. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest 1992; 89: 465-73.
18. Zwaginga J J, de Boer H C, IJseldijk M J W. Kerkhof A, Muller-Berghaus G, Gruhlichhenn J, SixmaJ J, de Groot P G. Thrombogenicity of vascular cells. Comparison between endothelial cells isolated from different sources and smooth muscle cells and fibroblasts. Arteriosclerosis 1990; 10(3): 437-48.
19. Ross R. The pathogenesis of atherosclerosis-an update. New Engl J Med 1986; 314(8): 488-500.
20. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 1992; 86(3): 723-29.
21. Clowes A W, Schwartz S M. Significance of quiescent smooth muscle migration in the injured rat carotic artery. Circulation Res 1985; 56: 139-45.
22. Bell L, Madri J A. Effect of platelet factors on migration of cultured bovine aortic endothelial and smooth muscle cells. Circu Res. 1989; 65(4): 1057-65.
23. Mosher D F. Physiology of thrombospondin. An Rev Med 1990; 41: 85-97.
24. Matsuno H, Stassen J M, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994; 90(5): 2203-6.
25. Clyman R I, Tannenbaum J, Chen Y Q et al. Ductus arteriosus smooth muscle cell migration on collagen: dependence on laminin and its receptors. J Cell Sci. 1994; 107(4): 1007-18.
26. Skinner M P, Raines E W, Ross R. Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagen-coated membranes. Am J Pathol 1994; 145(5): 1070-81.
27. Choi E T, Engel L, Callow A D, Sun S, Trachtenberg J, Santoro S, Ryan U S. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg. 1994; 19(1): 125-34.
28. Brown S L, Lundgren C H, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res. 1994; 28(12): 1815-20.
29. Fujio Y, Yamada F, Takahashi K, Shibata N. Altered fibronectin-dependent cell adhesion by PDGF accompanies phenotypic modulation of vascular smooth muscle cells. Biochem Biophys Res Commun. 1993; 196(2): 997-1002.
30. Jang Y, Lincoff A M, Plow E F, Topol E J. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol. 1994; 24(7): 1591-601.
31. Bendeck M P, Zempo N, Clowes A W, Galardy R E, Reidy M A. Smooth muscle cell migration and matrix metallloproteinase expression after arterial injury in the rat. Circulation Res 1994; 75: 539-45.
32. Wight T N, Hascall V C. Proteoglycans in primate arteries: III Characterisation of the proteoglycans synthesized by arterial smooth muscle cells in culture. J Cell Biol 1983; 96: 167-76.
33. Bell L, Madri J A. Effect of platelet factors on migration of cultured bovine aortic endothelial and smooth muscle cells. Circu Res 1989; 65: 1057-65.
34. Prescott M G, Webb R L, Reidy M A. Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol 1991; 139: 1291-96.
35. 5. Bell L, and Madri J A. Influence of the angiotensin system on endothelial and smooth muscle migration. Am J Pathol 1990; 137: 7-12.
36. Sato Y, Hamanaka R, Ono J, Kuwano M, Rifkin D B, Takaki R. The stimulatory effect of PDGF on vascular smooth muscle cell migration is mediated by the induction of endogenous basic FGF. Biochem Biophys Res Commun 1991; 174(3): 1260-66.
37. Bauriedel G, Dartsch P C, Voisard R, Roth D, Simpson J B, Höfling B, and Betz E. Selective percutaneous 'biopsy' of atheromatous plaque tissue for cell culture. Basic Res Cardiol 1989; 84: 3: 326-31.
38. Bauriedel G, Windstetter U, DeMaio SJ, Kandolf R, Höfling B. Migratory activity of human smooth muscle cells cultivated from coronary and peripheral primary and restenotic lesions removed by percutaneous atherectomy. Circulation 1992; 85: 2: 554-64.
39. Rifkin D B, Moscatelli D, Bizik J, Quarto N, Blei F, Dennis P, Flaumenhaft R, Mignatti P. Growth factor control of extracellular proteolysis. Cell Differ Dev 1990; 32: 313-8.
40. Boxman I L A, Quax P H A, Löwik C W G M, Papapoulos S E, Verheijen J H, Ponec M. Differential regulation of plasminogen activation in normal keratinocytes and SCC-4 cells by fibroblasts. J Invest Derm 1995; 104: 374-78.
41. Quax P H A, Pederson N, Masucci M Tet al. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 1991; 2: 793-803.
42. Jackson C L, Reidy M A. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann N Y Acad Sci 1992; 667: 141-150.
43. Clowes A W, Clowes M E T, Au Y P, Reidy M A, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67(1): 61-7.
44. Jackson C L, Raines E W, Ross R, Reidy M A. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Atherosclerosis Thromb 1993; 13: 1218-26.
45. Quax P H A, Khauw I M S L, Bakker T R, van Leeuwen R T J and Verheijen JH. Urokinase-type plasminogen activator is involved in smooth muscle cell migration in wounded cultures. Fibrinolysis 1994; 8(Suppl 1): abstract 417.
46. Lindner V, Olson N E, Clowes A W, Reidy M A. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J Clin Invest 1992; 90: 2044-49.
47. Fingerle J, Johnson R, Clowes A W, Majesky M W, Reidy M A. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotic artery. Proc Natl Acad Sci USA 1989; 86: 8412-16.
48. Jackson Ch L, Raines E W, Ross R, Reidy M A. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Atheroscler Thromb 1993; 13: 1218-1226.
49. Ferns G A A, Raines E W, Sprugel K H, Motani A S, Reidy M A, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-32.
50. Ferns GA, Reidy M A, Ross R. Balloon catheter deendothelialization of the nude rat carotic. Response to injury in the absence of functional T lymphocytes. Am J Path 1991; 138(4): 1045-57.
51. Yabkowitz R, Mansfield P J, Ryan U S, Suchard S J. Thrombospondin mediates migration and potentiates platelet-derived growth factor-dependent migration of calf pulmonary artery smooth muscle cells. J Cell Physiol. 1993; 157(1): 24-32.
52. Moscatelli D, Rifkin D B. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochem Biophys Acta 1988; 948: 67-85.
53. Matrisian L M. Metalloproteinases and their inhibitors in matrix remodelling. Trend Genet 1990; 6: 121-25.
54. He C, Wilhelm S M, Pentland A P, Mariner B L, Grant G A, Eisen A Z, and Goldberg G I. Tissue cooperation in a proteolytic cascade activation human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-36.
55. Alvarez O A, Carmichael D F, and deClerck Y A. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinam human tissue inhibitor of metalloproteinases. J Nat Cancer Inst 1990; 82(7): 589-95.
56. Mignatti P, Rifkin D B. Biology and biochemistry of proteinases in tumour invasion. Physiol Rev 1993; 73: 161-95.
57. Stricklin G P, Li L, Jancic V, Wenczak B A, Nanney L B. Localization of mRNAs representing collagenase and TIMP in sections of healing human burn wounds. Am J Pathol 1993; 143(6): 1657-66.
58. Salo T, Makela M, Kylmaniemi M, Autio-Harmainen H, Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest. 1994; 70(2): 176-82.
59. Bullen E C, Longaker M T, Updike D L, Benton R, Ladin D, Hou Z, Howard E W. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J In vest Dermatol 1995; 104: 236-40.
60. Jeffrey J J, Roswit W T, Ehlich L S. Regulation of collagenase production by steroids in uterine smooth muscle cells: an enzymatic and immunologic study. J Cell Physiol 1990; 143: 396-403.
61. Fisher S J, Cui T Y, Hartman L, Grahl K, Guo-Yang Z, Tarpey J, Damsky C H. Adhesive and degradative properties of human placental cytotrophoblast cells in vitro. J Cell Biol 1989; 109: 891-02.
62. LeMaire W J. Mechanism of mammalian ovulation. Steroids 1989; 54(5): 455-69.
63. Morioka N, Zhu C, Brannstrom M, Woessner J F, LeMaire W J. Mechanism of mammalian ovulation. Prog Clin Biol Res. 1989; 294: 65-85.
64. Kenagy R D, Nikkari S T, Welgus H G, Clowes A W. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Invest 1994; 93: 1987-93.
65. Southgate K M, Davies M, Booth R F G, Newby A C. Involvement of extracellular matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J 1992; 288: 93-9.
66. Danø, K Andreasen P A, Grondahl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
67. Astrup, T. Fibrinolysis: Past and present, a reflection of fifty years. Seminars in thrombolysis and hemostasis 1991; 17(3): 161-74.
68. Muellertz S. Fibrinolysis: an overview. Sem Thromb Hemost 1984; 10(1): 1-5.
69. Chapman H A, Reilly Jr J J, Kobzik L. Role of plasminogen activator in degradation of extracellular matrix protein by live human alveolar macrophages. Am Rev Respir Dis 1988; 137: 412-19.
70. Murphy G, Atkinson S, Ward G, Gavrilovic J, Reynolds J J. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992; 667: 1-12.
71. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB.
72. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 1990; 111(2): 757-63.
73. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol. 1989; 109(1): 309-15.
74. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990; 110: 767-75.
75. Uterman G. The mysteries of lipoprotein(a). Science 1989; 246: 904-10.
76. Gonzalez-Gronow M, Stack S, Pizzo S V. Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding. Arch Biochem Biophys 1991; 286: 2: 625-28.
77. Redlitz A, Plow A F. Receptors for plasminogen and t-PA: an update. In: Balieres Clinical Haematology 1995; 2: 313-27.
78. Miles L A, Dahlberg C M, Plescia J, Felez J, Kato K, Plow E F. Role of cell-surface lysines in plasminogen binding to cells: identification of a-enolase as a candidate plasminogen receptor. Biochemistry 1991; 30: 682-91.
79. Hoylaerts M, Rijken D C, Lijnen H R, Collen D. Kinetics of the activation of plasminogen by human tissue type plasminogen activator. J Biol Chem 1982; 257: 2912-19.
80. Hajjar K A, Jacovina A T. Molecular cloning of of an endothelial cell tissue plasminogen activator/plasminogen receptor: Annexin H-related protein. (Abstract 1602) Thromb Haemos 1993; 69(6), 989-95.
81. Kooistra T, Schrauwen Y, Arts J, Emeis J J. Regulation of endothelial cell t-PA synthesis and release. Int J Hematology 1994; 59: 233-55.
82. Tina Au Y P, Kenagy R D, Clowes A W. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis. J Biol Chem 1992; 267(5): 3438-44.
83. Clowes A W, Clowes M E T, Kirkman T R, Jackson C L, Au Y P, Kenagy R. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery. Circ Res 1992; 70(6); 1128-36.
84. Cajot J F, Kruithof E K O, Schleuning W D, Sordat B, Bachman F. Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 1986; 38: 719-27.
85. The human tissue plasminogen activator gene. Friezner-Degen S J, Rajput Bh, Reich E. J Biol Chem 1986; 261 (15): 6972-85.
86. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368(6470): 419-24.
87. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEBJ 1995; 9: 934-38.
88. Binnema DJ, Dooiewaard G, van lersel JJL. The contact system-dependent plasminogen activator from human plasma: identification and characterisation. Thromb Heamost 1990; 64: 390-97.
89. Sprengers E D, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-87.
90. Loskutoff D J, Sawdey M, Keeton M, Schneiderman J. Regulation of PAI-1 gene expresssion in vivo. Thromb Haemosts 1993; 70(1): 135-37.
91. Crutchley D J, Conanan L B. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells. J Biol Chem 1986; 261(1): 154-59.
92. Schleef R R, Loskutoff D J. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis 1988; 18: 328-41.
93. Reilly C E, McFall R C. Platelet derived growth factor and and transforming growth factor-b regulate plasminogen activator inhibitor -1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266(15): 9419-27.
94. Laug W E, Aebersold R, Jong A, Ribaout W, Bergman B, Baker J. Isolation of multiple types of plasminogen activator inhibitors from vascular smooth muscle cells. Thromb Heamost 1989; 61: 517-21.
95. Kooistra T, Bosma P J, Tons H A M, van den Berg A P, Meijer P, Prinsen H M G. Plasminogen activator inhibitor-1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 723-28.
96. Rømer J, Lund L R, Eriksen J, Ralfkjær E, Zeheb R, Gelehrter T D, Danø K, Kristensen P. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 1991; 97: 803-11.
97. Quax P H A, van Leeuwen R T J, Verspaget H W, Verheijen J H. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res 1990; 50, 1488-94.
98. Loskutoff D J. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206.
99. Meijer P, Pollet D E, Wauters J, Kluft C. Specificity of antigen assays of plasminogen activator inhibitor in plasma: innotest PAI-1 immunoassay evaluated. Clin Chem 1994; 40(1): 110-15.
100. Knudsen B S, Harpel P C, Nachman R L. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 1987; 80: 1082-89.
101. Mimuro J, Loscutoff D J. Purification of a protein from bovine plasma that binds to type-1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem 1989; 264(2): 936-39.
102. Zoellner H, Wojta J, Gallicchio M, McGrath K, Hamilton J A. Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells. Thromb. Haemostasis 1993; 69(2): 135-40.
103. Belin D. Biology and facultative secretion of plasminogen activator inhibitor-2. Thromb Haemost 1993; 70(1): 144-47.
104. Schwarz B S, Monroe M C, Levin E G. Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysacharide. Blood 1988; 71: 734-41.
105. Nathan C F. Secretory products of macrophages. J Clin Invest 1987; 79: 319-26.
106. Rijken D C. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. In: Balieres Clinical Haematology 1995; 2: 313-27.
107. Bachman F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen HR, Arnout J. eds. Thrombosis and haemostasis. Belgium: Leuven University Press. 1087-227.
108. Cunningham D D, Pulliam L, Vaughan P J. Protease nexin-1 and thrombin: injury-related processes in the brain. Thromb Haemost 1993; 70(1): 168-71.
109. Booth NA. The natural inhibitors of fibrinolysis. In: Bloom A L, Forbes C D, Thomas D P, Tuddenham E G D. eds. Haemostasis and thrombosis. Vol. I, 3rd Ed. Edinburgh: Churchill Livingstone.
110. Huisman LG, van Griensven JM, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 1995; 73(3): 466-71.
111. Kristensen T, Moestrup S K, Gliemann J, Bendtsen L, Sand O, Sottrup-Jensen L. Evidence that the newly cloned LDL receptor related protein (LRP) is the a2-macroglobulin receptor. FEBS 1990; 276: 151-55.
112. Willnow T E, Goldstein J L, Orth K, Brown M S, Herz J. LDL receptor-related protein and GP330 bind similar ligands, including plasminogen activator inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 1992; 267: 26172-80.
113. Andreasen P A, Sottrup-Jensen L, Kjøller L et al. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. Minireview. FEBS Letters 1994; 338: 239-45.
114. Hajjar K A and Reynolds C M. Alpha-fucose mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells. J Clin Invest 1994; 93: 703-10.
115. Kounnas M Z, Henklin J, Argraves W S, Strickland D K. LDL receptor-related protein/a2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem 1993; 268: 21862-67.
116. Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/a2-macroglobulin receptor. Proc Nat Acad Sci USA 1992; 89: 7422-26.
117. Hertz J, Clouthier D E, Hammer R E. Correction: LDL-receptor-related protein internalizes and degrades u-PA.PAI-1 complexes and is essential for embryo implantation. Cell 1993; 73: 428.
118. Grobmyer, S R, Kuo A, Orishimo M, Okada S S, Cines D B, Barnathan E S. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem 1993; 268(18): 13291-300.
119. Kuiper J, Otter M, van Zonneveld A J, Rijken D C, van Berkel Th J C. Tissue-type plasminogen activator and tissue-type plasminogen activator/plasminogen activator inhibitor type-1 complex are recognised by different receptor systems in the liver. Abstract. Circulation 1993; 88: 1-366.
120. Bu G, Williams S, Strickland D K, Schwartz A L. Low density lipoprotein-related protein/a2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 1992; 89: 7427-31.
121. Hertz J, Goldstein J L, Strickland D K, Ho Y K, Brown M S. A 39-kD protein modulates binding of ligands to LDL-receptor-related protein/a2-macroglobulin receptor. J Biol Chem 1991; 266: 21232-38.
122. Warshawsky I, Bu G, Schwartz A L. Identification of domains on the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein. J Biol Chem 1993; 268(29): 22046-54.
123. Laug W E. Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells. Thromb Haemost 1985; 53: 165-69.
124. van Leeuwen R T J, Quax P H A, Andreotti F et al. Different effects of endotoxin on mRNA levels of plasminogen activator inhibitor-1 in vivo and in cultured vascular smooth muscle cells (Submitted).
125. Quax P H A, van den Hoogen C M, Verheijen J H et al. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990; 265(26): 15560-63.
126. Laug W E, Cao X R, T'Ang A et al. Complex expression of the genes coding for plasminogen activators and their inhibitors in HeLa-smooth muscle cell hybrids. Cell Growth Differ. 1992; 3(3): 191-97.
127. Reuning U, Bang N U. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens Arteriosclerosis Thromb 1992; 12(10); 1161-70.
128. Padro T, Quax P H A, van den Hoogen C M, Roholl P, Verheijen J H, Emeis J J. Tissue-type plasminogen activator and its inhibitor in rat aorta; effect of endotoxin. Arterioscler Thromb 1994; 14: 1459-65.
129. Reilly J M, Siccard G A, Lucore C L. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg 1994; 19: 865-72.
130. Kenagy R D and Clowes A W. A possible role for MMP-2 and MMP-9 in the migration of primate arterial smooth muscle cells through native matrix. Ann N Y Acad Sci 1994; 732: 462-65.
131. Wojta J, Gallicchio M, Zoellner H et al. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost 1993; 70(3): 469-74.
132. Clowes A W, Clowes M M, Kirkman T R, Jackson C J, Tina Au Y P, Kenagy R. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotic artery. Circulation Res 1992; 70: 1128-36.
133. Au Y P, Dobrowolska G, Morris D R, Clowes A W. Heparin decreases activator protein-1 binding to DNA in part by posttranslational modification of Jun B. Circ Res 1994; 75(1): 15-22.
134. Reuning U, Little S P, Dixon E P, Bang N U. Effect of thrombin, the thrombin receptor activation peptide, and other mitogens on vascular smooth muscle cell urokinase receptor mRNA levels. Blood. 1994; 84(11): 3700-08.
135. Sawa H, Fujii S, Sobel B E. Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. Arteriosclerosis and Thromb 1992; 12: 1507-15.
136. Reilly C F, Broski J E. Differential effects of PDGF and PDGF-BB on vascular smooth muscle cells. BBRC. 1989; 160(3): 1047-54.
137. Carmeliet P F M. Physiological consequences of over- or underexpression of fibrinolytic system components in transgenic mice. In: Lijnen H R, Collen D, eds. Balieres Clinical Haematology. 1995; 8(2): 391-401.
138. Poggi A, Bellelli E, Salvatore L et al. Reduced pulmonary metastases of Lewis lung carcinoma in hPAI-1 transgenic mice. Abstract. Fibrinolysis 1994; 8(Suppl 1): 102.
139. Carmeliet P F M, Kieckens I, Schoonjans L, et al. Plasminogen activator inhibitor-1 gene-deficient mice: I. Generation by homologous recombination and characterization. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 1993, 92: 2746-60.
140. Carmeliet P, Stassen J M, Collen D, Meidell R S, Gerard R. Adenovirus-mediated gene transfer of rt-PA restores thrombolysis in t-PA deficient mice. Abstract. Fibrinolysis 1994; 8(Suppl 1): 101.
141. Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-32.
142. Docherty A J P, Murphy G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis 1990; 49: 469-79.
143. Mackay A R, Corbitt R H, Hartzler J L, Thorgeirsson U P. Basement membrane type IV collagen degradation: Evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990; 50: 5997-6001.
144. Mignatti P, Robbins E, Rifkin D B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986; 47287-498.
145. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-5.
146. Kolkenbrock H, Hecker-Kia A, Orgel D et al. A trypsin sensitive stromelysin isolated from rheumatoid synovial fluid is an activator for matrix metalloproteinases. Eur J Clin Chem Clin Biochem 1993; 31(10): 625-31.
147. Saari H, Suomalainen K, Lindy O, Konttinen Y T, Sorsa T. Activation of latent human neutrophil collagenase by reactive oxygen species and serine proteases. Biochem Biophys Res Comm 1990; 171: 979-87.
148. Davis G E. Identification of an abundant latent 94-kDa gelatin-degrading metalloprotease in human saliva which is activated by acid exposure: implications for a role in digestion of collagenous proteins. Arch Biochem Biophys 1991; 286(2): 551-54.
149. Docherty A J, Lyons A, Smith B J et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985; 318: 66-69.
150. Stetler-Stevenson W G, Krutzsch H C, Liotta L A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264(29): 17374-78.
151. Cawston T E, Murphy G, Mercer E, Galloway W A, Hazleman B L, Reynolds J J. The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor. Biochem J 1983; 211: 313-18.
152. DeClerck Y A. Purification and characterization of a collagenase inhibitor produced by bovine vascular smooth muscle cells. Arch Biochem Biophys 1988; 265(1): 28-37.
153. Edwards D R, Waterhouse P, Holman M L, Denhardt D T. A growth-responsive gene (16C8) in normal mouse fibroblasts homologous to a human collagenase inhibitor with erythroid-potentiating activity: evidence for inducable and constitutive transcripts. Nucl Acid Res 1986; 14: 8863-78.
154. Docherty A J P, Lyons A, Smith B J, Wright E M, Stephens P E, Harris T J R. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985; 318: 66-9.
155. Stetler-Stevenson W G, Bersch N, Golde D W. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett 1992; 296(2): 231-34.
156. Cawston T E, Galloway W A, Mercer E, Murphy G, and Reynolds J J. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981; 195: 159-65.
157. Brophy C M, Marks W H, Reilly J M, Tilson M D. Tissue inhibitor of metalloproteases (TIMP) is matrix associated in aortic tissue: report of a radioimmunoassay. Biochem Biophys Res Commun 1990; 167(3): 898-903.
158. Strongin A Y, Marmer B L, Grant G A, Goldberg G I. Plasma membrane-dependent activation of the 72-kD type IV collagenase is prevented by complex formation with TIMP-2. J Biol Chem 1992; 268(19): 14033-39.
159. Goldberg G I, Collier I E, Eisen A Z, Grant G A, Marmer B L, Wilhelm S M. Mosaic structure of the secreted ECM metalloproteases and interaction of the type IV collagenases with inhibitors. Matrix Suppl. 1992; 1: 25-30.
160. Sasaguri Y, Yanagi H, Fukuda S, Nakano R, Morimatsu M. Expression of oncogenes by smooth muscle cells in atherosclerotic lesions. Rinsho Byori [English Abstract]. 1990; 38(1): 19-25.
161. Yanagi H, Sasaguri Y, Sugama K, Morimatsu M, Nagase H. Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis. 1991; 91(3): 207-16.
162. Galis Z S, Muszynski M, Sukhova G K et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994; 75(1): 181-89.
163. Tina Au Y P, Montgomery K F, Clowes A W. Heparin inhibits collagenase gene expression mediated by phorbol esterresponsive element in primate arterial smooth muscle cells. Circ Res 1992; 70: 1062-67.
164. Kishi J, Hayakawa T. Synthesis of latent collagenase and collagenase inhibitor by bovine aortic medial expiants and cultured medial smooth muscle cells. Connect Tissue Res. 1989; 19(1): 63-76.
165. Sasaguri Y, Kakita N, Murahashi N, Kato S, Hiraoka K, Morimatsu M, Yagi K. Effect of linoleic acid hydroperoxide on production of matrix metalloproteinases by human aortic endothelial and smooth muscle cells. Atherosclerosis 1993; 100(2): 189-96.
166. Angel P, Baumann I, Stein B, Delius H, Rahmsdorf H J, Herrlich P. 12-O-tetradecanoyl-phorbol-13-acetate (TPA) induction of the human collagenase gene is mediated by an inducible enhancer element located on the 5′-flanking region. Mol Cell Biol 1987; 7: 2256-66.
167. Schorpp M, Mattei M G, Herr I, Gack S, Schaper J, Angel P. Structural organization and chromosomal localization of the mouse collagenase type I gene. Biochem J. 1995; 308 (1): 211-17.
168. Frisch SM, Ruley H E. Transcription from the stromelysin promoter is induced by interleukin-1 and repressed by dexamethasone. J Biol Chem 1987; 262: 16300-04.
169. Huhtala P, Tuuttila A, Chow LT, Lohi J, Keski-Oja J, Tryggvason K. Complete structure of the human gene for 92 kDa Type-IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem 1991; 266: 16485-490.
170. Campbell C E, Flenniken A M, Skup D, Williams B R G. Identification of a serum- and phorbol ester-responsive element in the murine tissue inhibitor of metalloproteinase gene. J Biol Chem 1991; 266: 7199-206.
171. Kerr L D, Olashaw N E, Matrisian L M. Transforming growth factor β1 and cAMP inhibit transcription of epidermal growth factor- and oncogene-induced transin RNA. J Biol Chem 1988; 263: 16999-7005.
172. Zempo N, Kenagy-R D, Au Y P, Bendeck M, Clowes MET, Reidy M A, Clowes A W. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery J Vasc Surg. 1994; 20(2): 209-17.
173. Okada Y; Katsuda S, Okada Y, Nakanishi I. An elastinolytic enzyme detected in the culture medium of human arterial smooth muscle cells. Cell Biol Int. 1993; 17(9): 863-69.
174. Pauly R R, Passaniti A, Bilato C et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994; 75(1): 41-54.
175. Huhtala P, Chow L T, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem 1990; 265: 11077-082.
176. Henney A M, Wakeley P R, Davies M J, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991; 88(18): 8154-58.
177. van Leeuwen R T J, Sperti G, Kluft C. Platelets and Platelet-Derived Growth Factor (PDGF) modulate mitosis and extracellular proteolysis in cultured vascular smooth muscle cells. Submitted.
178. Wilhelm S M, Collier I E, Marmer B L, Eisen A Z, Grant G A, Goldberg G I. SV-40 transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264(29): 17213-21.
179. Dawson S, Hamsten A, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Artherioscl Thromb 1991; 11: 183-90.
180. Ye S, Watts G F, Mandalia S, Humphries S E, Henney A M. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. British Heart Journal 1995; 73(3): 209-15.
181. Tanaka K, Honda M, Kuromochi T, Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis 1994; 107: 179-85.
182. Franklin S M, Faxon D P. Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coronary Artery Disease 1993; 4(3): 232-42.
183. Herrman J P R, Hermans W R M, Vos J, Serruys P W. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the holy grail? (Part I). Drugs 1993; 46(1): 18-52.
184. Herrman J P R, Hermans W R M, Vos J, Serruys P W. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the holy grail? (Part II). Drugs 1993; 46(2): 249-62.
185. Kowaluk E A, Seth P, Fung H L. Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle. J Pharmacol Exp Ther 1992; 262(3): 916-922.
186. Marks G S, McLaughlin B E, Nakatsu K, Brien J F. Direct evidence for nitric oxide formation from glyceryl trinitrate during incubation with intact bovine pulmonary artery. Can J Physiol Pharmacol 1992; 70(2): 308-11.
187. Kato S, Sasaguri Y, Morimatsu M. Down-regulation in the production of matrix metalloproteinase 1 by human aortic intimal smooth muscle cells. Biochem Mol Biol Int 1993; 31(2): 239-48.
188. Motoyama Y, Seki J, Katoh Y, Nishio M, Yoshida K. Effect of TFC-612, a 7-thia prostaglandin El derivative, on intimal thickening after endothelial injury with balloon catheter in rats. Atherosclerosis 1994; 108(2): 159-65.
189. Darlak K, Miller R B, Stack M S, Spatola R F, Gray R D. Thiolbased inhibitors of mammalian collagenase. J Biol Chem 1990; 265(9): 5199-205.
190. Shams N B, Hanninen L A, Kenyon K R. Increased gelatinolytic and caseinolytic activity in the thermally injured, nutritionally compromised rat cornea: detection of a 27-kDa lymphoreticular cell-associated caseinase. Curr Eye Res. 1994; 13(1): 11-19.
191. Odake S, Morita Y, Morikawa T, Yoshida N, Hori H, Nagai Y. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids. Biochem Biophys Res Commun. 1994; 199(3): 1442-6.
192. Tsuyuki H, Kajiwara K, Fujita A, Kumazaki T, Ishii S. Purification and characterization of Streptomyces griseus metalloendopeptidases I and II. J Biochem 1991; 110(3): 339-44.
193. Wolinsky H, Thurg SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 1990; 15: 475-81.
194. Bier J P, Zaleski P, Sasken H, Williams DO. A new bioabsorbable intravascular stent : in vitro assesment of hemodynamic and morphometric characteristics. Abstract. Circulation 1991; 84(Suppl 2): 197.
195. Matrisian LM, and Hogan B L M. Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development. Curr Top Devel Biol 1990; 24: 219-59.
196. Sasaguri Y, Murahashi N, Sugama K, Kato S, Hiraoka K, Satoh T, Isomoto H, Morimatsu M. Development-related changes in matrix metalloproteinase expression in human aortic smooth muscle cells. Lab Invest 1994; 71(2): 261-69.
197. Clyman R I, McDonald K A, Kramer RH. Integrin receptors on aortic smooth muscle cels mediate adhesion to fibronectin, laminin, and collagen. Circul Res 1990; 67: 175-86.
198. Ruoslahti E, Pierschbacher M D. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-96.
199. Yamamoto K, Yamamoto M. Cell adhesion receptors for native and denatured type I collagens and fibronectin in rabbit arterial smooth muscle cells in culture. Exp Cell Res 1994; 214(1): 258-63.
200. O'Brien K D, Allen M D, McDonald T O et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993; 92: 945-51.
201. Boudreau N, Turley E, Rabinovitch M. Fibronectin, hyaluronan, and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration. Dev Biol 1991; 143: 235-47.
202. Machovich R, Owen W G. The elastase-mediated pathway of fibrinolysis. Blood Coagulation and Fibrinol, 1990; 1: 79-90.